

ASX Announcement

15 July 2024

Peter Hall to be appointed as Non-Executive Director (addendum)

Melbourne, Australia – 15 July 2024: The Board of OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**), is pleased to announce that Mr Peter Hall will join the OncoSil Board as a Non-Executive Director by the end of August 2024.

Mr Hall is a London-based Australian financier, media proprietor and philanthropist. He founded investment firm Hunter Hall Investment Management in 1993, and acted as Chief Investment Officer and Executive Chairman during his 23 year tenure. He has contributed considerable time and donated millions of dollars to several animal conservation charitable causes. Peter is a Member of the Order of Australia for his philanthropic endeavours.

OncoSil’s Chairperson Mr Doug Cubbin said:

‘It is wonderful that we have Peter Hall coming to join as a Director in OncoSil Medical. We are in the middle of a turnaround and greatly supported by the medical community in helping bring a much-needed treatment for patients with pancreatic cancer’.

No resignation

No directors are resigning from the Board of OncoSil. The announcement of Peter Hall’s appointment earlier today erroneously used a default announcement header that included the word ‘resignation’. This has been corrected with this announcement.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699</p>
--	--	--

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>